Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring.
Status:
Completed
Trial end date:
2020-11-23
Target enrollment:
Participant gender:
Summary
In kidney transplant patients, CMV infection remains the leading infectious cause of
morbidity and mortality. Clinical and virological relapses are common and are involved in
chronic graft dysfunction. To date, it is not certain that secondary prophylaxis allows
reducing these relapses, although this prophylaxis is part of the current recommendations.
Our team has recently shown that the expansion of γδ T cells in peripheral blood during CMV
infection was correlated with the absence of virological and clinical relapses. Indeed, the
absence of relapse was associated in 94.7% of cases with the presence of γδ T cells expansion
while relapses occurred in about 90% of cases in the absence of γδ T cells expansion. These
results suggest that the indication and duration of secondary prophylaxis after the curative
treatment of CMV infection in kidney transplantation could be guided by the immune
surveillance of γδ T cells.